Therapy with @entity4184 in XXXX with refractory sprue.

@entity1 @entity137 @entity404 @entity1593 @entity8884 @entity19012 @entity784 @entity228 @entity7017 @entity194 @entity4184 @entity617
INTRODUCTION: @entity1593 ( @entity1593 ) is a rare @entity8884 , which often requires long-term corticosteroid treatment. Locally acting @entity4184 could replace systemic @entity228 therapy and reduce @entity137 in @entity1 with @entity1593 . AIMS: To evaluate the efficacy and @entity137 of @entity4184 in @entity1 with @entity1593 . @entity1 AND METHODS: Clinical and histological data from @entity1 with @entity1593 who received @entity4184 were analyzed. @entity1593 was defined as villous @entity194 in spite of a strict gluten-free diet persisting for >6 months or requiring earlier therapeutic intervention. RESULTS: We identified 9 @entity1 (1 with @entity7017 , 4 with @entity1593 type I without and 3 with @entity1593 type II with signs of early @entity784 and 1 with @entity404 -positive sprue-like @entity784 ), who received 9 mg/day of @entity4184 (range 6-12) for 24 months (1-60), and 7 of whom had an initial treatment with 40 mg/day of @entity617 (30-60) for 4 months (1-144). The initial body mass index was 18 (13.1-22.8) and increased similarly under @entity617 [21.5 (14.9-26.7), p < 0.05] and @entity4184 therapy [21 (18-27.2), p < 0.05]. The stool frequency per day also decreased similarly from 6 (2-8) to 2 (1-3) and 2 (1-5), each p < 0.05, under @entity617 and @entity4184 therapy, respectively. Two @entity1 with @entity1593 type II did not respond and 7, including all 4 with @entity1593 type I, were clinically stable with @entity4184 therapy. @entity19012 in 1 @entity1 was the only adverse effect of @entity4184 therapy. CONCLUSIONS: @entity4184 may be an effective treatment option in @entity1 with @entity1593 type I, which can stabilize the clinical condition similar to @entity617 .
